Promises of Protein Kinase Inhibitors in Recalcitrant Small-Cell Lung Cancer: Recent Scenario and Future...

Area of Science:

• Oncology
• Molecular Biology
• Immunology

Background:

• Small cell lung cancer (SCLC) exhibits resistance to conventional treatments.
• Current targeted therapies and immune checkpoint inhibitors (ICIs) provide only marginal survival benefits for SCLC patients.
• ICIs are effective only in a subset of SCLC patients, highlighting the need for improved therapeutic strategies.

Purpose of the Study:

• To comprehensively review the role of dysregulated kinases in SCLC.
• To explore the potential of kinase inhibitors as targeted therapeutic agents for SCLC.
• To examine the involvement of kinases in enhancing ICI-mediated antitumor immune responses.

Main Methods:

• Extensive literature review on kinase dysregulation in SCLC.
• Analysis of pharmacological kinase inhibitors used in SCLC targeted therapy.
• Review of studies investigating the role of kinases in ICI efficacy and clinical trials.

Main Results:

• Kinases play critical roles in cellular functions relevant to therapeutic responses in SCLC.
• Dysregulated kinases represent potential targets for novel SCLC therapies.
• Kinase inhibitors may enhance the efficacy of ICIs in SCLC treatment.

Conclusions:

• Understanding kinase signaling pathways is essential for overcoming SCLC therapeutic resistance.
• Targeted inhibition of specific kinases holds promise for improving SCLC patient outcomes.
• Combination strategies involving kinase inhibitors and ICIs warrant further clinical investigation for SCLC.